PROCEEDINGS

Open Access

Epigenome wide association study of SNP–CpG interactions on changes in triglyceride levels after pharmaceutical intervention: a GAW20 analysis

Jenna Veenstra[1,2], Anya Kalsbeek[1,2], Karissa Koster[2], Nathan Ryder[2], Abbey Bos[1], Jordan Huisman[2], Lucas VanderBerg[2], Jason VanderWoude[2,3] and Nathan L. Tintle[2*]

Abstract

In the search for an understanding of how genetic variation contributes to the heritability of common human disease, the potential role of epigenetic factors, such as methylation, is being explored with increasing frequency. Although standard analyses test for associations between methylation levels at individual cytosine-phosphate-guanine (CpG) sites and phenotypes of interest, some investigators have begun testing for methylation and how methylation may modulate the effects of genetic polymorphisms on phenotypes. In our analysis, we used both a genome-wide and candidate gene approach to investigate potential single-nucleotide polymorphism (SNP)–CpG interactions on changes in triglyceride levels. Although we were able to identify numerous loci of interest when using an exploratory significance threshold, we did not identify any significant interactions using a strict genome-wide significance threshold. We were also able to identify numerous loci using the candidate gene approach, in which we focused on 18 genes with prior evidence of association of triglyceride levels. In particular, we identified *GALNT2* loci as containing potential CpG sites that moderate the impact of genetic polymorphisms on triglyceride levels. Further work is needed to provide clear guidance on analytic strategies for testing SNP–CpG interactions, although leveraging prior biological understanding may be needed to improve statistical power in data sets with smaller sample sizes.

Background

Methylation plays a major role in gene regulation through epigenetic modifications at specific cytosine-phosphate-guanine (CpG) residues within the regulatory regions of genes and, consequently, may influence the transcriptional activity [1]. In brief, methylation occurs when a methyl group is transferred to the DNA via a family of DNA methyltransferases. The majority of DNA methylation occurs oncytosines, which immediately precedea guanine nucleotide (ie, CpG site). These CpG sites occur frequently throughout the genome and have been linked to both single-nucleotide polymorphisms (SNPs) and epigenetic changes [2].In particular, DNA methylation may lead to different influences on gene activities depending on the surrounding genetic sequence [3]. Because SNPs near the CpG site may alter methylation levels, the statistical interaction between SNPs and CpG sites may explain varying gene expression across individuals. Prior research shows that DNA methylation in the interleukin-4 receptor is associated with asthma, but this association is further explained by the presence or absence of a nearby SNP [4]. A study focusing on obesity found the interaction between CpG sites in an enhancer region interacts with CpG creating SNP sites

* Correspondence: Nathan.Tintle@dordt.edu
[2]Department of Mathematics and Statistics, Dordt College, 498 4th Ave. NE, Sioux Center, IA 51250, USA
Full list of author information is available at the end of the article

Veenstra *et al. BMC Proceedings* 2018, **12**(Suppl 9):58

Page 194 of 258

in an obesity-risk haplotype, which helps explain obesity/ Type 2 Diabetes [5].

As part of GAW20, we were provided access to a data set of methylation, SNPs, and triglyceride levels over 2 time periods, along with numerous related covariates. In particular, the study measured triglyceride levels before and after pharmaceutical intervention. Given the well-known relationship between triglycerides and many different cardiometabolic diseases, including cardiovascular disease [6], we chose to look for evidence of methylation at CpG sites that potentially modulate the impact of nearby SNPs on changes in triglyceride levels.

Methods
Sample population and variables
The sample consisted of 670 individuals from a pedigree sample provided as part of GAW20 for whom all analyzed variables were available. We considered 6 covariates (age, observation center, smoking status, mass spectrometry DX client [MSDX] International Diabetes Federation [IDF] score, fasting time at baseline, and high-density lipoprotein [HDL] at baseline) the majority of which were significantly associated with baseline triglyceride (TG) in this sample. The primary response variable of interest was TG level at baseline (visit 1 or 2). For variables with up to 2 measurements at baseline (HDL [baseline], TG [baseline]), we used the average value if both measurements were available, or the only available measurement if only one was available.

Models
The modeling process was done in 2 stages. The first stage model resulted in a single residual TG value for each person, while the second stage resulted in approximately 700,000 models (one for each SNP that passed standard genome-wide association study [GWAS] quality control [QC] criteria: Hardy-Weinberg equilibrium p value$> 1 \times 10^{-6}$, minor allele frequency $> 1\%$, SNP missing data rate $< 5\%$).

In the first stage, we used the *lmekin* function from the *coxme* package in R [7] to predict the change in log-transformed TG levels [$y = \ln (baseline)$]. In cases where 2 separate TG measurements were available for the baseline, we natural-log (ln)-transformed the data before averaging. Baseline ln-transformed TG levels was predicted by the 6 covariates listed earlier and accounted for the familial relationships in the model through the use of the kinship matrix. We then saved the resulting "residual" value ($r_i = \hat{y}_i - y_i$) for each of the $i = 1,\ldots, 670$ individuals in our analysis.

The second stage predicted the residuals ($r_i's$) from stage 1 based on the number of minor alleles ($SNP_j = 0, 1, 2$) and methylation scores ($CPG_j \in [0,1]$) with a separate model

for each SNP_j, CPG_j pair using the *lm* function in R [7]. In particular, the second stage model for SNP_j, CPG_j pair was:

$$r_j = \beta_{S_j} SNP_j + \beta_{C_j} CPG_j + \beta_{S_j C_j} SNP_j CPG_j \qquad (1)$$

where $\beta_{S_j C_j}$ is the estimate of interaction effect between SNP_j and CPG_j. SNP_j, CPG_j pairs were made by assigning each SNP passing QC to its nearest CpG site, resulting in approximately 700,000 pairs, with some CpG sites assigned to multiple SNPs.

Statistical analysis
Statistical significance of the interaction term in Eq. 1 was assessed using an F test, essentially testing whether the statistical interaction provided significantly more evidence of association with changes in TG levels versus a model with only main-effects terms. Versions of Eq. 1 without the interaction term were also run. We started by using a generally accepted, but stricter and conservative, genome-wide significance level of 5×10^{-8}. We followed up this analysis by using a more liberal and exploratory significance level of 1×10^{-4} in our genome-wide interaction analysis.

We followed this genome-wide analysis with a candidate gene study focusing on 18 gene regions (containing 423 unique SNP-CpG sites) that have been shown to be associated with TGs in previous genome-wide association studies via searches at http://www.ebi.ac.uk/gwas. Throughout the candidate gene analysis, we used a significance level of 0.05. As part of the candidate gene analysis we also collapsed all the CpG sites within each gene region (50 kb on either side of the gene) by using 5 different methods (mean, minimum, maximum, median, and sum-squares of the CpG values as the CPG value in the model) to evaluate the potential impact of different ways of summarizing methylation evidence for each SNP. For the SNPs that demonstrated a significant interaction for more than one of the collapsing methods used, we then looked at the interactions between all CpG sites within the region and those SNPs.

Results
Genome-wide approach
No interaction term p values were significant when using the conservative 5×10^{-8} threshold. However, 58 SNP-CpG pairs showed significant interactions using the more liberal 1×10^{-4} significance level. Table 1 summarizes 25 loci that include regions of SNPs that are colocalized and within genes (total of 44 interactions). The median p value of the interaction term across all sites was 0.504 and a lambda value of 1.02, showing no inflation of test statistics.

Veenstra *et al. BMC Proceedings* 2018, **12**(Suppl 9):58

Page 195 of 258

Table 1 Summary of 25 loci with significant interactions between SNP and CpG site at the 1×10^{-4} significance level[a]

Chr	Region that includes SNPs (bp)	# of significant interactions	Smallest interaction p value (rs#: cg#)	Nearest genes[b]	Prior GWAS evidence[c]
1	118,384,931	1	8.87×10^{-5} (rs10923477: cg04904531)	SPAG17	Cardiometabolic (CM) [10]
1	176,244,329	1	9.17×10^{-5} (rs12078421: cg00529480)	LOC730102, SEC16B	CM [11]
1	241,422,395	1	7.97×10^{-5} (rs10926962: cg20140940)	CEP170	
1	243,623,480–243,632,536	3	5.45×10^{-6} (rs12141949: cg23956499)	KIF26B, LOC105373266	CM [12]
2	169,660,479	1	6.32×10^{-5} (rs1059261: cg09479286)	DHRS9, LRP2	CM [13]
2	228,572,906	1	1.52×10^{-5} (rs11680053: cg13774987)	SPHKAP, LOC105373918	
3	62,027,949	1	7.47×10^{-5} (rs1309430?: cg02315619)	PTPRG	CM [14]
3	65,613,288–65,616,308	2	6.31×10^{-6} (rs1156024: cg21573947)	MAGI1, ILF2P1	CM [15]
3	120,418,689–120,430,978	4	3.03×10^{-5} (rs6438504: cg13640423)	B4GALT4, UPK1B, B4GALT4-AS1	
5	174,537,630–174,544,483	4	2.17×10^{-5} (rs4868496: cg16698913)		
6	71,439,742	1	9.10×10^{-5} (rs13196394: cg21039196)	SMAP1, SLC25A6P6, LOC100419975	CM [16]
6	127,678,516–127,680,041	2	4.94×10^{-5} (rs3798853: cg21774964)	ECHDC1, RNF146, RPL5P18, LOC105377994, LOC107986641, YWHAZP4	
10	25,274,245	1	8.54×10^{-5} (rs2035888: cg05845435)	PRTFDC1, THNSL1, ENKUR	CM [17]
12	70,654,838	1	8.80×10^{-5} (rs7300641: cg04586418)	TPH2, TBC1D15	
12	90,830,205–90,838,946	5	2.59×10^{-5} (rs12318079: cg04373948)	LOC105369901, LOC105369900	CM [18]
13	93,851,561	1	6.27×10^{-5} (rs9561551: cg21762236)	GPC6, DCT	CM [10]
14	31,886,488–32,181,048	5	5.79×10^{-6} (rs10141122: cg01642415)	AKAP6	CM [11]
14	38,728,932	1	6.17×10^{-5} (rs10140832: cg09400985)	MIA2, YTHDF2P1, LOC100313942, CTAGE5	
14	63,424,087	1	3.30×10^{-5} (rs4902250: cg04285935)	SYNE2	CM [19]
15	22,717,850	1	3.60×10^{-5} (rs17785279: cg02476674)	SNRPN, RPL5P1	CM [10]
15	74,146,110	1	2.30×10^{-5} (rs7183492: cg19385388)	TMEM266, NRG4	CM [20]
16	86,596,651	1	7.26×10^{-5} (rs7500034: cg04279689)	BANP	
18	25,713,049–25,713,439	2	4.05×10^{-5} (rs4799651: cg11963233)		
21	29,961,249	1	5.02×10^{-5} (rs2268206: cg06212876)	GRIK1, GRIK1-AS2	CM [21]
22	35,532,777	1	7.29×10^{-6} (rs736720: cg11855664)	PVALB, IFT27, LOC105373021, LOC107958578	CM [21]

[a]Because of linkage disequilibrium structure in these regions each loci can be assumed to have a single independent association (detailed results not shown)
[b]Based ongene_infofile provided by GAW20, supplemented by additional information from dbSNP (http://ncbi.nlm.nih.gov/snp). The nearest genes were always within 50 kb of the most significant SNP
[c]Based on search at http://www.ebi.ac.uk/gwas

Veenstra *et al. BMC Proceedings* 2018, **12**(Suppl 9):58

Page 196 of 258

Candidate gene approach

In our data, there are 18 genes (containing 423 SNPs for which data was available) previously shown to be associated with TG levels. Table 2 summarizes the results of fitting Eq. 1 with an interaction term, as well as a version of Eq. 1 without the interaction term.

Thirteen of the 18 candidate genes show at least modest ($p < 0.05$) evidence of statistical interaction between nearby methylation values and SNPs within the gene. The most significant SNP is in *FADS3* (rs1675102) and has a minor allele frequency of 0.28. The interaction is such that additional copies of the minor allele lead to a decreased impact of methylation on changes in TG levels.

Table 3 shows the results of collapsing all the CpG sites within each gene region through the minimum method, which uses the minimum CpG value of all CpG sites within 50 kb of the gene. Compared to the other 4 methods, the minimum method resulted in more significant interactions (44) than did the other 4 collapsing methods, which on average only have 23 significant interactions (detailed results not shown).

We identified 176 unique SNPs in significant interactions for more than 1 of the 5 different CpG collapsing methods as found in Table 4. In total, there are 176 unique significant SNP × CpG interactions. *GALNT2* had the largest number of significant results with 69 interactions, where 1 of the 69 interactions is the most significant with

a p value of 0.000142. The SNP in this interaction (rs6677241) has a minor allele frequency of 0.026. The interaction results in an increased impact of methylation on TG levels for every additional allele.

Discussion

Although no significant SNP–CPG interactions were identified when using strict, genome-wide significance thresholds (5×10^{-8}), use of a more exploratory approach identified many genes previously shown to be associated with cardiometabolic traits (1×10^{-4}). A candidate gene approach, using a significance level of 0.05, identified loci in 13 genes with modest evidence for SNP-CpG interactions on baseline TG levels. Furthermore, by using the collapsing methods, we were able to identify potentially interesting SNPs for additional exploration. Using only these SNPs, our examination of all CpG sites within each gene region resulted in 176 significant unique SNP-CpG pairs. In every case, the SNP-CpGp value was smaller than both the SNP and CpGp values from the noninteraction model. This suggests that using SNP-CpG pairs may identify SNPs that would not be identified by traditional GWAS techniques. The gene *GALNT2*, had the most significant interactions with 69. SNPs in *GALNT2* were previously identified as associated with TG levels, high- and low-density lipoprotein cholesterol [8]. One study shows that promoter methylation

Table 2 Summary of 18 genes with previous evidence of association with triglyceride levels

Gene	Chr	# of significant interactions[a] (total)	Smallest interaction p value	SNP $p$value[b]	SNP location (bp)	Interaction (rs#:cg#)[c]
APOA1	11	1 (16)	0.0316	0.296	116,707,207	rs563838:cg24984312
APOA5	11	1 (12)	0.0316	0.296	116,707,207	rs563838:cg24984312
APOB	2	0 (13)	0.0511	0.124	21,318,003	rs312042:cg23349726
APOC3	11	1 (17)	0.0316	0.296	116,707,207	rs563838:cg24984312
BUD13	11	0 (13)	0.0866	0.904	116,570,686	rs1784042:cg19442415
CETP	16	1 (19)	0.0184	0.502	56,971,665	rs17241126:cg05062620
CLIP2	7	0 (2)	0.656	0.662	73,771,865	rs2718277:cg07814763
DOCK7	1	3 (75)	0.0261	0.341	63,034,240	rs12122434:cg00161770
FADS1	11	1 (16)	0.00430	0.740	61,581,397	rs444803:cg11606466
FADS2	11	1 (26)	0.00430	0.740	61,581,397	rs444803:cg11606466
FADS3	11	1 (20)	0.00351	0.830	61,710,585	rs1675102:cg16084190
GALNT2	1	2 (123)	0.0409	0.605	230,224,139	rs11588595:cg11424376
GCKR	2	1 (7)	0.0435	0.0846	27,730,170	rs17706100:cg22903471
LPL	8	1 (24)	0.0463	0.497	19,794,163	rs17091651:cg04035597
MLXIPL	7	0 (11)	0.106	0.373	73,083,725	rs884843:cg12958963
OTOR	20	1 (46)	0.0290	0.469	16,748,375	rs1883698:cg07500957
PLTP	20	2 (35)	0.0251	0.983	44,576,565	rs3795126:cg17262492
TRIB1	8	0 (8)	0.135	0.638	126,445,881	rs13255114:cg22644321

[a]With a significance level of 0.05
[b]From a model with only main effects terms for CpG and SNP (ie, Eq. 1 without the interaction term)
[c]Duplicates are a result of the overlapping nature of several of the genes

Veenstra *et al. BMC Proceedings* 2018, **12**(Suppl 9):58

Page 197 of 258

Table 3 Summary of CpG results after collapsing using the minimum method

Gene	Chr	# of significant interactions[a](Total)	Significant SNPs with > 1 methods[b]	Smallest interaction p value (rs#)	SNP p value[c]	SNP location (bp)	# of CpGs within region collapsed
APOA1	11	0 (45)	1	0.292 (rs633389)	0.381	116,667,337	57
APOA5	11	4 (43)	0	0.02564 (rs10488699)	0.00487	116,632,500	80
APOB	2	3 (43)	3	0.00286 (rs693)	0.0851	21,232,195	31
APOC3	11	0 (46)	0	0.111 (rs632153)	0.119	116,710,239	68
BUD13	11	5 (46)	2	0.0252 (rs12279373)	0.0155	116,600,400	63
CETP	16	4 (43)	0	0.0199 (rs247609)	0.984	56,973,461	47
CLIP2	7	1 (16)	1	0.0143 (rs4298392)	0.791	73,862,441	74
DOCK7	1	9 (38)	0	0.0215 (73862441)	0.306	63,049,819	39
FADS1	11	4 (18)	1	0.000440 (rs174534)	0.217	61,549,458	107
FADS2	11	3 (19)	1	0.00314 (rs174534)	0.214	61,549,458	109
FADS3	11	0 (21)	1	0.102 (rs7927548)	0.461	61,690,901	45
GALNT2	1	7 (138)	3	0.00154 (rs10779837)	0.194	230,327,568	96
GCKR	2	1 (9)	0	0.0480 (rs4665383)	0.0490	27,791,555	32
LPL	8	0 (53)	0	0.157 (rs10102876)	0.869	19,779,785	17
MLXIPL	7	0 (10)	1	0.0826 (rs7782054)	0.135	73,028,759	98
OTOR	20	0 (46)	3	0.0510 (rs16998203)	0.792	16,739,519	20
PLTP	20	3 (24)	0	0.0327 (rs11086984)	0.955	44,511,627	91
TRIB1	8	0 (32)	0	0.0802 (rs17663005)	0.798	126,464,388	38

[a]With a significance level of 0.05
[b]The SNP was found to be significant with more than 1CpG collapsing method. Refer to methods section
[c]From a model with only main effects terms for CpG and SNP (ie, Model 1 without the interaction term)

of *GALNT2* is associated with a higher risk of coronary heart disease [9].

There are some limitations to our analysis. First, to manage computational resources, we began by predicting baseline TG levels by kinship and covariates, yielding residuals for each individual, which we used for assessing impact of methylation and genetic variation. Other alternatives to this methodology may exist. We used an exploratory significance threshold for the genome-wide analysis, relative to the vast majority of GWAS-type analyses published today. Although this can lead to more false-positive results, we did find a number of "subthreshold" loci of potential interest suggesting the need for studies with larger sample sizes and more sensitive statistical methods to draw out these loci of interest. The minimum method of summarizing methylation in a region nearby to a gene showed promise, although further work is needed to more fully evaluate the many

Table 4 Summary of 176[a] interaction pairs

Gene	Chr	# of significant interactions[b](total)	Smallest interaction p value	SNP pvalue[c]	CpG pvalue[c]	SNP location (bp)	Interaction (rs#:cg#)
APOA1	11	11 (57)	0.00678	0.591	0.310	116,759,824	rs12294191:cg07700644
APOB	2	9 (31)	0.00316	0.414	0.518	21,205,457	rs10172650:cg26118553
BUD13	11	31 (126)	0.00103	0.787	0.837	116,652,301	rs4417316:cg14371153
CLIP2	7	7 (74)	0.00318	0.214	0.983	73,671,288	rs3735504:cg08495433
FADS1	11	4 (52)	0.0193	0.0921	0.0831	61,549,458	rs174534:cg07689907
FADS2	11	10 (53)	0.00228	0.217	0.432	61,549,458	rs174534:cg11880646
FADS3	11	9 (45)	0.0183	0.861	0.690	61,698,488	rs7928792:cg03046346
GALNT2	1	69 (288)	0.000142	0.780	0.998	230,337,887	rs6677241:cg03961853
MLXIPL	7	16 (98)	0.00220	0.613	0.298	73,041,886	rs6460045:cg03842980
OTOR	20	10 (60)	0.00934	0.196	0.581	16,702,501	rs761228:cg07364906

[a]As a result of overlap of gene regions for *FADS1* and *FADS2*, 3 significant interactions are counted twice
[b]With a significance level of 0.05
[c]From models with only the main effect term for CpG or SNP. Refer to methods

Veenstra *et al. BMC Proceedings* 2018, **12**(Suppl 9):58

Page 198 of 258

options. Regardless, leveraging prior biological evidence (eg, via the candidate gene approach) may be of potential effect when testing for SNP–CPG interactions.

Conclusions

Even with "subthreshold" significance, our results go a long way toward showing the need for statistical models that leverage prior biological information. Our study shows that a mediated effect of SNPs on methylation is a possible explanation for changes in TG levels. With this knowledge, more studies with greater sample sizes can be performed as well as wet lab experimentation to confirm the relationship. As we learn more about the effect an individual's genotype has on their health, there is greater opportunity for personalized medicine to be an effective treatment strategy.

Availability of data and materials
The data that support the findings of this study are available from the Genetic Analysis Workshop (GAW), but restrictions apply to the availability of these data, which were used under license for the current study. Qualified researchers may request these data directly from GAW.

About this supplement
This article has been published as part of BMC Proceedings Volume 12 Supplement 9, 2018: Genetic Analysis Workshop 20: envisioning the future of statistical genetics by exploring methods for epigenetic and pharmacogenomic data. The full contents of the supplement are available online at https://bmcproc.biomedcentral.com/articles/supplements/volume-12-supplement-9.

Authors' contributions
All authors participated in the conception of this idea, have read and approved the final manuscript. JWW wrote most of the code. JV and AK analyzed the data. JV wrote the manuscript and made revisions. NLT provided support throughout the project.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
[1]Department of Biology, Dordt College, 498 4th Ave. NE, Sioux Center, IA 51250, USA. [2]Department of Mathematics and Statistics, Dordt College, 498 4th Ave. NE, Sioux Center, IA 51250, USA. [3]Department of Computer Science, Dordt College, 498 4th Ave. NE, Sioux Center, IA 51250, USA.

Published: 17 September 2018

References
1. Rösl F1, Arab A, Klevenz B, zurHausen H. The effect of DNA methylation on gene regulation of human papillomaviruses. J Gen Virol. 1993;74(Pt 5):791–801.
2. Zhi D, Aslibekyan S, Irvin MR, Claas SA, Borecki IB, Ordovas JM, Absher DM, Arnett DK. SNPs located at CpG sites modulate genome-epigenome interaction. Epigenetics. 2013;8(8):802–6.
3. Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38(1):23–38.
4. Soto-Ramírez N, Arshad SH, Holloway JW, Zhang H, Schauberger E, Ewart S, Patil V, Karmaus W. The interaction of genetic variants and DNA methylation of the interleukin-4 receptor gene increase the risk of asthma at age 18 years. Clin Epigenetics. 2013;5(1):1.
5. Bell CG, Finer S, Lindgren CM, Wilson GA, Rakyan VK, Teschendorff AE, Akan P, Stupka E, Down TA, Prokopenko I, et al. Integrated genetic and epigenetic analysis identifies haplotype-specific methylation in the FTO type 2 diabetes and obesity susceptibility locus. PLoS One. 2010;5(11):e14040.
6. Lindman AS, Veierød MB, Tverdal A, Pedersen JI, Selmer R. Nonfasting triglycerides and risk of cardiovascular death in men and women from the Norwegian counties study. Eur J Epidemiol. 2010;25(11):789–98.
7. R-Project: "R," 2016. [Online]. https://www.r-project.org. Accessed Feb 2017.
8. Guo T, Yin RX, Huang F, Yao LM, Lin WX, Pan SL. Association between the DOCK7, PCSK9 and GALNT2 gene polymorphisms and serum lipid levels. Sci Rep. 2016;6:19079.
9. Peng P, Wang L, Yang X, Huang X, Ba Y, Chen X, Guo J, Lian J, Zhou J. A preliminary study of the relationship between promoter methylation of the ABCG1, GALNT2 and HMGCR genes and coronary heart disease. PLoS One. 2014;9(8):e102265.
10. Comuzzie AG, Cole SA, Laston SL, Voruganti VS, Haack K, Gibbs RA, Butte NF. Novel genetic loci identified for the pathophysiology of childhood obesity in the Hispanic population. PLoS One. 2012;7(12):e51954.
11. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S, Buchkovich ML, Yang J, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518(7538):197–206.
12. Williams SR, Hsu FC, Keene KL, Chen WM, Nelson S, Southerland AM, Madden EB, Coull B, Gogarten SM, Furie KL, et al. Shared genetic susceptibility of vascular-related biomarkers with ischemic and recurrent stroke. Neurology. 2016;86(4):351–9.
13. Sung YJ, de Las Fuentes L, Schwander KL, Simino J, Rao DC. Gene-smoking interactions identify several novel blood pressure loci in the Framingham heart study. Am J Hypertens. 2015;28(3):343–54.
14. Carty CL, Keene KL, Cheng YC, Meschia JF, Chen WM, Nalls M, Bis JC, Kittner SJ, Rich SS, Tajuddin S, et al. Meta-analysis of genome-wide association studies identifies genetic risk factors for stroke in African Americans. Stroke. 2015;46(8):2063–8.
15. Zheng JS, Arnett DK, Lee YC, Shen J, Parnell LD, Smith CE, Richardson K, Li D, Borecki IB, Ordovás JM, et al. Genome-wide contribution of genotype by environment interaction to variation of diabetes-related traits. PLoS One. 2013;8(10):e77442.
16. Rühle F, Witten A, Barysenka A, Huge A, Arning A, Heller C, Krümpel A, Mesters R, Franke A, Lieb W, et al. Rare genetic variants in SMAP1, B3GAT2, and RIMS1 contribute to pediatric venous thromboembolism. Blood. 2017;129(6):783–90.
17. Yu B, Zheng Y, Alexander D, Manolio TA, Alonso A, Nettleton JA, Boerwinkle E. Genome-wide association study of a heart failure related metabolomic profile among African Americans in the atherosclerosis risk in communities (ARIC) study. Genet Epidemiol. 2013;37(8):840–5.
18. Smith NL, Felix JF, Morrison AC, Demissie S, Glazer NL, Loehr LR, Cupples LA, Dehghan A, Lumley T, Rosamond WD, et al. Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Circ Cardiovasc Genet. 2010;3(3):256–66.
19. Christophersen IE, Rienstra M, Roselli C, Yin X, Geelhoed B, Barnard J, Lin H, Arking DE, Smith AV, Albert CM, et al. Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. Nat Genet. 2017;49(6):946–52.
20. Nagy R, Boutin TS, Marten J, Huffman JE, Kerr SM, Campbell A, Evenden L, Gibson J, Amador C, Howard DM, et al. Exploration of haplotype research consortium imputation for genome-wide association studies in 20,032 generation Scotland participants. Genome Med. 2017;9(1):23.
21. Wang KS, Liu X, Zheng S, Zeng M, Pan Y, Callahan K. A novel locus for body mass index on 5p15.2: a meta-analysis of two genome-wide association studies. Gene. 2012;500(1):80–4.